Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 425 Shares

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 425 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $46.43, for a total value of $19,732.75. Following the sale, the insider owned 138,257 shares of the company’s stock, valued at approximately $6,419,272.51. The trade was a 0.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Wednesday, February 11th, Dennis Cho sold 5,000 shares of Twist Bioscience stock. The shares were sold at an average price of $49.93, for a total transaction of $249,650.00.
• On Tuesday, February 3rd, Dennis Cho sold 1,099 shares of Twist Bioscience stock. The stock was sold at an average price of $46.58, for a total transaction of $51,191.42.
• On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The stock was sold at an average price of $34.56, for a total transaction of $11,197.44.

Twist Bioscience Trading Down 6.1%

NASDAQ TWST opened at $45.40 on Wednesday. The firm’s fifty day moving average price is $44.19 and its 200 day moving average price is $34.92. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $57.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of -35.47 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience’s revenue was up 16.9% compared to the same quarter last year. On average, sell-side analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

TWST has been the subject of a number of research analyst reports. Evercore upped their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Finally, Barclays increased their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Axxcess Wealth Management LLC purchased a new position in shares of Twist Bioscience during the 4th quarter worth approximately $201,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $242,000. Empowered Funds LLC purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $58,000. VARCOV Co. acquired a new position in Twist Bioscience during the fourth quarter worth $263,000. Finally, Wellington Management Group LLP raised its position in Twist Bioscience by 171.2% in the fourth quarter. Wellington Management Group LLP now owns 813,122 shares of the company’s stock worth $25,792,000 after acquiring an additional 513,309 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.